Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, necessitating early detection for effective management. This study explores the efficacy of various biomarkerbased approaches in the early diagnosis of COPD. We conducted a comparative analysis of existing biomarkers, including inflammatory cytokines, proteomic profiles, and genetic markers, assessing their sensitivity and specificity in identifying early-stage COPD. A cohort of high-risk individuals was monitored, with biomarker levels correlated to pulmonary function tests and clinical outcomes. Our findings indicate that a combination of specific inflammatory markers and proteomic signatures enhances early detection accuracy compared to traditional methods. Additionally, this approach facilitates personalized treatment strategies by identifying at-risk populations. This research underscores the potential of biomarker-based diagnostics in revolutionizing COPD management, paving the way for timely interventions that could significantly improve patient outcomes and reduce healthcare burdens associated with advanced disease stages. Further studies are warranted to validate these findings in diverse populations.